Abstract:Purpose To prospectively evaluate the efficacy of ultrasound (US)-guided microwave ablation (MWA) for benign breast lesions (BBLs) ≥ 2 cm and explore the possible factors affecting the volume reduction rate (VRR) of treated lesions. Materials and Methods From November 2013 to December 2017, a total of 86 patients with 110 biopsy-proved BBLs with a minimum dimension of 2 cm were performed MWA under local anesthesia. After procedure, patients were followed up at 3, 6 and 12-month by US imaging examination via 2D-US combining contrast-enhanced ultrasound (CEUS) and magnetic resonance imaging (MRI). Results MWA was successfully performed in all cases including 53 lesions adjacent to the skin, pectoralis and areola. The median ablation time was 4.9 ± 2.9 mins (ranging 1.7-18.3 mins). The longest diameter of tumors was 2.6 ± 0.6 cm (ranging 2.0-6.0 cm). Complete ablation was achieved in all lesions by CEUS and MRI. After the 12-month follow-up, only 48.0% (50/104) of BBLs was palpable, compared with 98.1% (102/104) of those before MWA. The volume reduction ratios at 12-month follow-up were 80.2±13.1% for all the BBLs. Cosmetic outcomes were reported as good or excellent in 100%. No complications were found in all patients even the BBLs adjacent to important structures. In regression analysis, lesion location adjacent to areola was significantly and positively associated with 12-months VRR of lesions, independent of age, lesion volume prior to MWA, hydro-dissection application, energy applied per volume, lesion location adjacent to skin or lesion location adjacent to pectoralis (β=8.0; 95%CI, 2.5, 13.4; P=0.005). Conclusion For ≥ 2 cm BBLs, MWA was achieved significant volume reduction and satisfying cosmetic outcomes without injury to skin, pectoralis and areola. Thereby, MWA is a valuable technique for large BBLs with minimal invasion. Besides, lesion location adjacent to areola was a favorable factor for 12-months VRR.

Microwave Ablation of Benign Breast Tumors: a Prospective Study with Minimum 12 Months Follow-Up.

Ultrasound-guided Percutaneous Microwave Ablation for 755 Benign Breast Lesions: a Prospective Multicenter Study

Percutaneous Microwave Ablation Versus Breast Conserving Surgery for 2-5Cm Breast Cancer: A Two-Center, Retrospective Study

Microwave ablation without subsequent lumpectomy versus breast-conserving surgery for early breast cancer: a propensity score matching study

Microwave Ablation (MWA) For≥ 2 Cm Benign Breast Lesions (Bbls)

US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study

Ultrasound Guided Percutaneous Microwave Ablation of Benign Breast Lesions.

Therapeutic effect of ultrasound-guided percutaneous microwave ablation for benign breast lesions

Microwave Ablation Versus Nipple Sparing Mastectomy for Breast Cancer ≤5 cm: A Pilot Cohort Study

Us-Guided Percutaneous Microwave Ablation of Renal Cell Carcinoma: Intermediate-Term Results

Microwave Ablation of Benign Thyroid Nodules: 3-Year Follow-Up Outcomes

Volume Reduction for ≥2 Cm Benign Breast Lesions after Ultrasound-Guided Microwave Ablation with a Minimum 12-Month Follow-Up

Percutaneous Microwave Ablation: A Viable Local Therapy for Breast Cancer Involving the Skin/Nipple-Areola Complex?

Ultrasound-guided Microwave Ablation for Abdominal Wall Metastatic Tumors： A Preliminary Study

Microwave Ablation for Benign Thyroid Nodules with Cosmetic Problems and Related Factors for Post-Ablative Complete Relief: a Two-Center Retrospective Study

[Clinical Evaluation of Ultrasound-Guided Percutaneous Microwave Ablation of Splenic Tumors].

Preliminary study of ultrasound-guided percutaneous microwave ablation therapy for benign breast nodules

Learning Curve of Microwave Ablation for Liver Cancers

Percutaneous Microwave Ablation for Liver Tumours Adjacent to the Marginal Angle.

Is Partial Ablation Appropriate for Benign Thyroid Nodules? A Retrospective Study with Long-Term Follow-Up after Microwave Ablation

Microwave Ablation Vs. Surgical Resection for Treatment Naïve Hepatocellular Carcinoma Within the Milan Criteria: a Follow-Up of at Least 5 Years